1251 - 5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomized clinical trials

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Moti Ramgopal, MD, FACP, FIDSA

Medical Director
Midway Specialty Care Center
Fort Pierce, Florida, United States

AW

Anson Wurapa, MD

Infectious Disease Specialists of Atlanta
Decatur, Georgia, United States
AB

Axel Baumgarten, MD

Center for Infectious Diseases (zidp)
Berlin, Berlin, Germany
MB

Mezgebe Berhe, MD, MPH

Infectious Disease specialist
North Texas Infectious Diseases Consultants
Dallas, Texas, United States
AP

Anton Pozniak, MD, FRCP

Professor
Chelsea and Westminster Hospital
London, England, United Kingdom
CO

Chloe Orkin, MBChB, FRCP, MD

Queen Mary University of London
London, England, United Kingdom
JT

Juan Manuel Tiraboschi, PhD

Bellvitge University Hospital
Barcelona, Catalonia, Spain
Debbie P. Hagins, MD, FAPCR, AAHIVS

Family Medicine Specialist
Georgia Department of Public Health, Coastal Health District, Chatham CARE Center, Savannah, GA, USA
Savannah, Georgia, United States
HH

Hailin Huang, PhD

Gilead Sciences, Inc.
Foster City, California, United States
KA

Kristin Andreatta, MSc

Gilead Sciences
Foster City, California, United States
NU

Nathan Unger, PharmD, AAHIVP

Gilead Sciences
Foster City, California, United States
JH

Jason Hindman, PharmD, MBA

Gilead Sciences
Foster City, California, United States
HM

Hal Martin, MD

Exec Director, Virology Clinical Research
Gilead Sciences
Foster City, California, United States
JB

Jared Baeten, MD, PhD

Gilead Sciences
Foster City, California, United States
Olayemi Osiyemi, MD

President
Triple O Research Institute
West Palm Beach, Florida, United States